Eypt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eypt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eypt Today - Breaking & Trending Today
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $19.74, but opened at $13.89. EyePoint Pharmaceuticals shares last traded at $12.99, with a volume of 4,364,816 shares traded. Analyst Upgrades and Downgrades A number of equities research analysts have […] ....
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $21.53, but opened at $20.26. EyePoint Pharmaceuticals shares last traded at $20.84, with a volume of 50,221 shares changing hands. Analyst Ratings Changes Several research analysts recently commented on the company. Mizuho […] ....
FNY Investment Advisers LLC bought a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) in the 4th quarter, HoldingsChannel reports. The fund bought 1,210 shares of the company’s stock, valued at approximately $27,000. Several other institutional investors have also recently added to or reduced their stakes in the business. Deutsche Bank […] ....
Legato Capital Management LLC lessened its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Free Report) by 23.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 59,347 shares of the company’s stock after selling 18,054 shares during the period. Legato Capital Management LLC owned […] ....
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) issued its earnings results on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27, Zacks reports. The firm had revenue of $14.03 million during the quarter, compared to the consensus estimate of $8.71 million. EyePoint Pharmaceuticals had a negative return […] ....